oncocarta panel v1.0 sequenom massarray (Sequenom)
90
Structured Review
Sequenom
oncocarta panel v1.0 sequenom massarray
Oncocarta Panel V1.0 Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oncocarta+panel+v1%2E0+sequenom+massarray/oncocarta+panel+v1+0/pmc05087596-114-62-65
Average 90 stars, based on 1 article reviews
Oncocarta Panel V1.0 Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oncocarta+panel+v1%2E0+sequenom+massarray/oncocarta+panel+v1+0/pmc05087596-114-62-65
Average 90 stars, based on 1 article reviews
oncocarta panel v1.0 sequenom massarray - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Selection:Article Title: MEK plus PI3K/mTORC1/2 therapeutic efficacy is impacted by TP53 mutation in preclinical models of colorectal cancer Article Snippet: Patient selection and genotyping of tumor samples All patients with pathologically confirmed metastatic CRC refractory to standard therapy referred to phase I clinical trials at the Molecular Therapeutic Research Unit of Vall d' Hebron Institute of Oncology had archived formalin-fixed paraffin-embedded (FFPE) tumor samples analyzed for targeted molecular aberrations KRAS/NRAS/BRAF/PIK3CA mutations were identified using the TheraScreen® molecular diagnostic assay (DxS) or the Clinical Proteomics:Article Title: MEK plus PI3K/mTORC1/2 therapeutic efficacy is impacted by TP53 mutation in preclinical models of colorectal cancer Article Snippet: Patient selection and genotyping of tumor samples All patients with pathologically confirmed metastatic CRC refractory to standard therapy referred to phase I clinical trials at the Molecular Therapeutic Research Unit of Vall d' Hebron Institute of Oncology had archived formalin-fixed paraffin-embedded (FFPE) tumor samples analyzed for targeted molecular aberrations KRAS/NRAS/BRAF/PIK3CA mutations were identified using the TheraScreen® molecular diagnostic assay (DxS) or the Formalin-fixed Paraffin-Embedded:Article Title: MEK plus PI3K/mTORC1/2 therapeutic efficacy is impacted by TP53 mutation in preclinical models of colorectal cancer Article Snippet: Patient selection and genotyping of tumor samples All patients with pathologically confirmed metastatic CRC refractory to standard therapy referred to phase I clinical trials at the Molecular Therapeutic Research Unit of Vall d' Hebron Institute of Oncology had archived formalin-fixed paraffin-embedded (FFPE) tumor samples analyzed for targeted molecular aberrations KRAS/NRAS/BRAF/PIK3CA mutations were identified using the TheraScreen® molecular diagnostic assay (DxS) or the Diagnostic Assay:Article Title: MEK plus PI3K/mTORC1/2 therapeutic efficacy is impacted by TP53 mutation in preclinical models of colorectal cancer Article Snippet: Patient selection and genotyping of tumor samples All patients with pathologically confirmed metastatic CRC refractory to standard therapy referred to phase I clinical trials at the Molecular Therapeutic Research Unit of Vall d' Hebron Institute of Oncology had archived formalin-fixed paraffin-embedded (FFPE) tumor samples analyzed for targeted molecular aberrations KRAS/NRAS/BRAF/PIK3CA mutations were identified using the TheraScreen® molecular diagnostic assay (DxS) or the |